|
|
Volumn 94, Issue 1, 2002, Pages 15-16
|
|
Is there less resistance on the chemoresistance front?
a
a
NONE
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
CA 125 ANTIGEN;
DNA TOPOISOMERASE INHIBITOR;
GLYCOPROTEIN P;
IMATINIB;
MONOCLONAL ANTIBODY;
OREGOVOMAB;
PLATINUM DERIVATIVE;
TAXANE DERIVATIVE;
TOPOTECAN;
BONE MARROW SUPPRESSION;
CANCER;
CANCER RECURRENCE;
CANCER RESEARCH;
COMPLICATION;
CONTROLLED STUDY;
DNA DAMAGE;
DRUG RESEARCH;
DRUG TARGETING;
DRUG TOXICITY;
DRUG TRANSPORT;
GENETICS;
HOST;
HUMAN;
IMMUNE RESPONSE;
NOTE;
OVARY CANCER;
PATIENT CARE;
PRIORITY JOURNAL;
SECOND CANCER;
SOLID TUMOR;
UNITED STATES;
|
|
EID: 0037005953
PISSN: 00278874
EISSN: None
Source Type: Journal
DOI: 10.1093/jnci/94.1.15 Document Type: Note |
|
Times cited : (2)
|
|
References (0)
|